Revalesio Names Bert van den Bergh President

Revalesio Corporation strengthened its executive leadership with the appointment of Bert van den Bergh as President. Mr. van den Bergh brings extensive industry experience to Revalesio as the company accelerates the development and commercialization of its therapeutic, RNS60. He previously spent 30 years with Eli Lilly & Company where he served as President of Neuroscience Products, President of European Operations and General Manager for the United Kingdom and Germany.

"Over the years, I've learned that it's very unusual to discover -- and develop a pharmaceutical with the potential to have a 'systems effect' on human biology. The more I learned about Revalesio and its breakthrough technology, the more excited I became to be a part of the company," said van den Bergh. "I've never seen a therapeutic with the wide-ranging potential of RNS60. I'm looking forward to helping expedite its development and commercialization and excited by the prospect of bringing relief to people with chronic and life-threatening illnesses."

At Eli Lilly & Company, van den Bergh was instrumental in the development, commercialization and lifecycle management of innovative pharmaceuticals like Cymbalta, Prozac, Strattera and Zyprexa. He has led business operations around the world, and has a proven track record of successfully commercializing novel medicines.

"Adding someone with Bert's experience and industry credibility to lead our team is a significant milestone for Revalesio," said Eric Russell, Chairman and CEO of Revalesio Corporation. "He will play a critical role as we engage our global research partners in the next phase of clinical trials for multiple sclerosis, asthma and Alzheimer's disease. It's an exciting time for Revalesio as we move forward in bringing RNS60 to market."

In addition to his role at Revalesio, van den Bergh serves on a variety of nonprofit boards and advisory committees, including the Pulmonary Vascular Research Institute, Mental Health America and Peers for Progress.

RNS60 contains highly potent charge-stabilized nanostructures (CSNs) that decrease inflammation and cell death. The therapeutic is starting clinical phase II studies for multiple sclerosis and asthma with multiple global research partners. Additional clinical studies are planned for acute myocardial infarctions and Alzheimer's disease. Revalesio recently announced promising research tying RNS60 to the treatment of Alzheimer's disease and other forms of dementia.

Contact Revalesio to learn more about RNS60 and the opportunity for research partnerships.

About Revalesio Corporation
Revalesio is a clinical-stage biomedical company dedicated to improving health. Based in Tacoma, Washington, Revalesio partners with leaders in biomedical research around the world to develop RNS60 to address a variety of therapeutic needs. The privately held company was founded by the Russell Family in 2006 and has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of charge-stabilized nanostructures (CSNs) in treating neuroinflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit 

Gabe Boeckman
Voxus PR
(253) 444-5377
Email Contact 

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.